Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board ...

Recursion's approach is intriguing, as evidenced by the fact that several of the world's largest pharmaceutical companies ...

Recursion Pharmaceuticals (RXRX) saw a sharp uptick in trading as investors looked ahead to the CEO's upcoming presentation at a major AI conference. The focus is on how the company’s AI strategy and ...

In recent developments, Recursion Pharmaceuticals unveiled advances in its AI platform for drug discovery, forming collaborations with major pharmaceutical groups including Sanofi, Roche/Genentech, ...

Recursion Pharmaceuticals, Inc ( ($RXRX) ) has released its Q3 earnings. Here is a breakdown of the information Recursion Pharmaceuticals, Inc ...

Recursion Pharmaceuticals NASDAQ:RXRX Chief Executive Officer Christopher Gibson sold 100,000 shares of Class A Common Stock on October 23, 2025, at a price of $5.70, totaling $570,000. The sale ...

Recursion Pharmaceuticals, Inc (($RXRX)) has held its Q3 earnings call. Read on for the main highlights of the call. Recursion Pharmaceuticals, ...

We recently published 10 Big Names Beating Wall Street at its Own Game. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best performers on Monday. Recursion Pharmaceuticals soared by 13.99 ...

Recursion Pharmaceuticals (NASDAQ:RXRX), a $2.3 billion market cap biotech company currently trading at $5.31, saw Chief Executive Officer Christopher Gibson sell 100,000 shares of Class A Common ...

In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...